Amaramet Adverse Reactions

Digestive Tract: Gastrointestinal (GI) symptoms including nausea, vomiting, diarrhea, abdominal pain and anorexia. These symptoms are the most common in the initial stage of treatment and generally resolve spontaneously. Occasionally, temporary dose reduction may be useful. Because GI symptoms during therapy initiation appear to be dose-related, they may be decreased by gradual dose escalation and by having patients take Glimepiride + Metformin tablet with meals.
Because significant diarrhea and/or vomiting may cause dehydration and prerenal azotemia, under such circumstances, Glimepiride + Metformin tablet should be temporarily discontinued. For patients who have been stabilized on Glimepiride + Metformin tablet, nonspecific GI symptoms should not be attributed to therapy unless intercurrent illness or lactic acidosis has been excluded.
Nervous System: About 3% of patients can feel taste disturbance or metallic taste during the initial stage of treatment with Glimepiride + Metformin tablet but they generally resolve spontaneously. Especially, transient vision disorder may occur due to change of blood glucose.
Dermatologic Reactions: Occasionally, allergic or pseudo-allergic reactions (e.g., itching, urticaria or rashes) may occur. These reactions are almost mild but may develop into serious reaction with dyspnea and a fall in blood pressure, sometimes progressing to shock. In the event of urticaria, a physician must therefore be notified immediately.
Blood: Changes in the blood picture may occur. Rarely, thrombopenia, in isolated cases, leukopenia or hemolytic anemia (e.g., erythrocytopenia, granulocytopenia, agranulocytosis) may develop. Because it is reported that aplastic anemia and pancytopenia may occur in sulfonylureas, careful monitoring should be performed. If these occur, the medication should be discontinued and adequate treatment taken.